Stopping oral therapy in atopic dermatitis remission led to early relapse; biologics held longer

Design

Systematic review and network meta-analysis

Population

Patients with atopic dermatitis in remission on systemic therapy, 55 studies

Primary outcome

Maintenance of EASI-75 at 16 to 52 weeks after withdrawal, reduction or interval extension

Effect

Early relapse after stopping oral therapies; lowest loss of EASI-75 with lebrikizumab withdrawal or interval extension

This systematic review and network meta-analysis, published in early October, included 55 studies of patients with atopic dermatitis who had reached remission on systemic therapy. It compared withdrawal, dose reduction and dosing interval extension with continuation, using maintenance of EASI-75 at 16 to 52 weeks as the outcome. The network analysis drew on 9 studies covering 13 regimens and 2585 observations.

Stopping oral systemic therapies was followed by early relapse. Biologics, by contrast, maintained responses better after withdrawal or interval extension. Lebrikizumab withdrawal and interval extension carried a lower risk of losing EASI-75 than the other strategies in the network.

This changes how a remission visit goes. For a patient in remission on a biologic, spacing out doses is a reasonable conversation, which matters for cost and access in India. For a patient on an oral systemic drug, stopping abruptly risks a quick flare, so plan for that if a break is needed, for example around pregnancy. The comparisons rest on few studies and indirect links, and no guideline yet sets a standard tapering schedule.

• Warn patients in remission on an oral systemic drug that stopping is likely to be followed by early flare.
• Consider dosing interval extension rather than continuation for patients in stable remission on a biologic.
• Plan topical rescue and early review when any systemic treatment is stopped or spaced out.
• Where a break is required, such as before pregnancy, agree a flare plan in advance.
• Discuss cost: spacing biologic doses may make long-term treatment more affordable.

Why it matters

Most patients in remission ask whether they can reduce treatment, and the answer differs sharply between oral drugs and biologics.

Don't overread it

The ranking of individual biologics relies on indirect comparisons from few studies and does not establish one as best.

The statistics, in plain English

A network meta-analysis compares treatments that were never tested head to head by linking them through common comparators. That makes its rankings more uncertain than a direct trial. With only nine studies in the network, the lebrikizumab ranking in particular rests on limited data.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.